Saturday, May 23, 2015

ROTH starts Vascular Biogenics at buy

ROTH starts Vascular Biogenics at buy

May 22, 2015 by · Leave a Comment 

Tweet ROTH Capital Partners has initiated coverage of Vascular Biogenics (NASDAQ:VBLT) with a “buy” rating and a $13 price target. The stock closed at $5.05 on Thursday. Vascular has two technology platforms targeting oncology and immunology indications. The first platform is Vascular Targeting System (VTS), which is a multi-component gene therapy design targeting vascular endothelial […]

ROTH adds Michael Higgins to biotech research team

ROTH adds Michael Higgins to biotech research team

May 6, 2015 by · Leave a Comment 

Tweet Michael Higgins has joined ROTH Capital Partners as a senior research analyst covering the biotechnology and specialty pharmaceuticals sectors. Prior to joining ROTH, Mr. Higgins covered the biopharmaceuticals sector for Rodman & Renshaw, where his coverage included generic drug companies as well as clinical-stage biotechnology companies. In a statement, Mr. Higgins said his goal […]

Roth starts uniQure at buy

Roth starts uniQure at buy

April 14, 2015 by · Leave a Comment 

Tweet Roth Capital Partners has launched coverage of uniQure NV (NASDAQ:QURE) with a “buy” rating and $38 price, saying its AAV-based gene therapy could usher in a new era in the treatment of multiple chronic and fatal disorders. The stock closed at $29.03 on Monday. “The 3Q and 4Q15 reads from its Hemophilia B and […]

Roth starts Argos Therapeutics at buy

Roth starts Argos Therapeutics at buy

March 26, 2015 by · Leave a Comment 

Tweet Roth Capital Partners has initiated coverage of Argos Therapeutics (NASDAQ:ARGS) with a “buy” rating and $21 price target, saying the company has the potential to be one of the leaders in cancer immunotherapy. The stock closed at $8.92 on Wednesday. Argos’ proprietary technology platform, Arcelis, is based on the work of Nobel Prize-winning co-founder, […]

Roth starts Celladon at buy

Roth starts Celladon at buy

March 5, 2015 by · Leave a Comment 

Tweet Roth Capital Partners has initiated coverage of Celladon (NASDAQ:CLDN) with a “buy” rating and 12-month price target of $70. The stock closed at $19.64 on Wednesday. Celladon is expected to announce potentially pivotal trial results from a 250-patient heart failure gene therapy trial (CUPID 2) in April 2015, writes analyst Elemer Piros. The company’s […]

Roth starts Zosano Pharma at buy

Roth starts Zosano Pharma at buy

February 23, 2015 by · Leave a Comment 

Tweet Roth Capital Partners has initiated coverage of Zosano Pharma (NASDAQ:ZSAN) with a “buy” rating and price target of $20. The stock closed at $11.09 on Friday. Zosano Pharma has a microneedle “patch” platform that provides injection-like results with a more tolerable delivery vehicle. “The impetus for our buy rating is the potential of the […]

Elemer Piros joins Roth biotech team

Elemer Piros joins Roth biotech team

February 19, 2015 by · Leave a Comment 

Tweet Elemer Piros has joined Roth Capital Partners as a senior research analyst covering the biotechnology sector. Prior to joining Roth, Dr. Piros was interim CEO of eMMUNITY, an immunotherapy startup company. He was previously a senior biotechnology analyst at Rodman & Renshaw and Burrill Securities. Dr. Piros was ranked as the No. 1 biotechnology […]

Roth starts Spark Therapeutics at buy

Roth starts Spark Therapeutics at buy

February 19, 2015 by · Leave a Comment 

Tweet Roth Capital Partners has initiated coverage of Spark Therapeutics (NASDAQ:ONCE) with a “buy” rating and 12-month price target of $71, saying Spark’s gene therapy platform could revolutionize the treatment of genetic disorders. The stock closed at $46 on Wednesday. “Spark Therapeutics, a less than two-year old company, could become the first to secure FDA […]

Roth resumes coverage of Neptune at buy

Roth resumes coverage of Neptune at buy

January 30, 2015 by · Leave a Comment 

Tweet Roth Capital Partners has resumed coverage of Neptune Technologies & Bioressources (NASDAQ:NEPT; TSX:NTB) with a “buy” rating and $5 price target. The stock closed at $1.83 on Thursday. Neptune is a leading provider of krill oil (omega-3 supplements) with its premium product, Neptune Krill Oil (NKO). “With a new state-of-the-art manufacturing plant, and a […]

Roth starts Titan Pharma at buy

Roth starts Titan Pharma at buy

January 20, 2015 by · Leave a Comment 

Tweet Roth Capital Partners has launched coverage of Titan Pharmaceuticals (OTCBB:TTNP) with a “buy” rating and a price target of $1.25. The stock closed at 47 cents on Monday. “The impetus for our buy rating is the potential of the company’s developmental Probuphine six-month implant of buprenorphine for the treatment of opioid dependence,” writes analyst […]

Next Page »

Email Newsletters with Constant Contact
Google+